FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |

Amgen Inc. patents

The following is a sampling of recent Amgen Inc. patent applications (USPTO Patent Application #, Patent Title) sorted by month.

August 2012 - Amgen Inc. patents

20120216878 - Valve for controlling the flow of steam and other fluids
20120220583 - Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
20120220585 - Heterocyclic compounds and their uses
20120220586 - Heterocyclic compounds and their uses
20120213779 - Fgf21 mutants and uses thereof
20120213797 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
20120214204 - Cell culture media for uvc exposure and methods related thereto
20120208760 - Thrombopoietic compounds
20120195879 - Carrier immunoglobulins and uses thereof
20120195985 - Glycine transporter-1 inhibitors

July 2012 - Amgen Inc. patents

20120190666 - Heteroaryl compounds as pikk inhibitors
20120190829 - Antigen binding proteins capable of binding thymic stromal lymphopoietin
20120183546 - Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
20120183561 - Alpha-4-beta-7 heterodimer specific antagonist antibody
20120177646 - Fgf21 mutants and uses thereof
20120177662 - Alpha-4-beta-7 heterodimer specific antagonist antibody
20120178685 - Fgf21 mutants and uses thereof

June 2012 - Amgen Inc. patents

20120165334 - Indole/benzimidazole compounds as mtor kinase inhibitors
20120156725 - Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
20120148531 - Fused heterocyclic derivatives and methods of use
20120142605 - Methods of treating psoriasis

May 2012 - Amgen Inc. patents

20120136163 - method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole
20120129771 - Peptides and related molecules that modulate nerve growth factor activity
20120121591 - Selective and potent peptide inhibitors of kv1.3
20120122847 - Aurora kinase modulators and method of use
20120115811 - Phenylanaline amide derivatives useful for treating insulin-related diseases and conditions
20120116057 - Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
20120107275 - Fused heterocyclic derivatives and methods of use
20120108587 - Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof

April 2012 - Amgen Inc. patents

20120088749 - S1p receptor modulating compounds and use thereof

March 2012 - Amgen Inc. patents

20120070432 - Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
20120071474 - Inhibitors of pi3 kinase
20120065185 - Substituted alkylamine derivatives and methods of use

February 2012 - Amgen Inc. patents

20120039880 - Fragmentation resistant igg1 fc-conjugates
20120040983 - Phthalazine compounds as p38 map kinase modulators and methods of use thereof
20120034237 - Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
20120034657 - Thrombopoietic compounds
20120027765 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
20120028877 - Self-buffering protein formulations
20120028917 - Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistant cancer

January 2012 - Amgen Inc. patents

20120020918 - Il-1 family variants
20120020976 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
20120020975 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
20120021459 - Feed media
20120009190 - Identification and method for using the pre-ligand assembly domain of the il-17 receptor
20120010256 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
20120010594 - Drug delivery device
20120003216 - Fgf21 mutants and uses thereof
20120003237 - Wise binding agents and epitopes

August 2011 - Amgen Inc. patents

20110201602 - Protein kinase modulators and method of use
20110195895 - Fgf21 mutants and uses thereof
20110190330 - Spirocyclic gpr40 modulators

July 2011 - Amgen Inc. patents

20110166331 - Il-17 receptor a antigen binding proteins

June 2011 - Amgen Inc. patents

20110151579 - Secreted epithelial stromal-1 molecules and uses thereof

May 2011 - Amgen Inc. patents

20110117053 - Method of modulating fibroblast accumulation or collagen deposition
20110118250 - Beta-secretase modulators and methods of use
20110118252 - Substituted amide derivatives and methods of use
20110104757 - Human anti-b7rp1 neutralizing antibodies
20110105499 - Pyrazolo-pyrazinone compounds and methods of use thereof
20110105498 - Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators and methods of use thereof

April 2011 - Amgen Inc. patents

20110097305 - Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
20110097318 - Solid-state protein formulation
20110097336 - Methods for modulating mannose content of recombinant proteins
20110092504 - Inhibitors of pi3 kinase
20110086834 - Alkynyl alcohols as kinase inhibitors
20110081339 - Methods of using il-17 receptor a antibodies

March 2011 - Amgen Inc. patents

20110052604 - Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

February 2011 - Amgen Inc. patents

20110044986 - Anti-amyloid antibodies and uses thereof
20110045587 - Toxin peptide therapeutic agents
20110033472 - Tumor endothelial marker 5-alpha molecules and uses thereof
20110034487 - Cxcr3 antagonists



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Amgen Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Amgen Inc. with additional patents listed. Browse our Agent directory for other possible listings.